



mounjaro[®]

(tirzepatide) injection 0.5 mL

2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

Instructions for the Oracle Health EHR System

Using EHR Capabilities to Support Prescribing and
Continuing Treatment on Mounjaro[®] (tirzepatide)

EHR=electronic health record.

INDICATION

Mounjaro (tirzepatide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

SELECT IMPORTANT SAFETY INFORMATION

WARNING: RISK OF THYROID C-CELL TUMORS

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.

Lilly

A MEDICINE COMPANY

Contents

Background and Considerations	2
Utilizing EHR Prescribing Workflow Capabilities	3
Oracle Health Instructions	5
How to Save Mounjaro® (tirzepatide) as a "Favorite" in Oracle Health.....	5
Creating a Message Within Message Center.....	7
Provider Reminders (Special Instructions, Discern Alert).....	12
Patient Instructions.....	19
Disclaimers	22
Notes	23
Important Safety Information	24

Background and Considerations

One of the main goals of the EHR workflow instructions for Mounjaro® (tirzepatide) is to help support consistency in how it is prescribed. Ensuring that prescriptions are completed accurately is essential to prevent pharmacy delays or rejections.

Additionally, the workflow instructions will assist with how key messages are delivered to care team members and patients—including treatment-specific follow-ups and savings card resources.

The Oracle Health EHR system includes capabilities that may be customized to help address most of these needs by facilitating prescribing, providing patient follow-up reminders, and improving awareness of the Mounjaro Savings Card. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions.

This document is not intended to provide any clinical advice or recommendations, which are solely the responsibility of the health system and its healthcare providers. This information is meant to provide technical guidance and recommendations to better understand a patient population. The process outlined in the technical instructions is variable and not all steps will apply to every health system. Any steps or settings below that are not part of a health system's standard process should be excluded or modified accordingly. Any questions should be directed to the appropriate service provider. The practice is solely responsible for implementing, testing, monitoring, and maintaining the ongoing operation of any EHR tools.

These instructions are specific to adult patients with type 2 diabetes and to the Oracle Health EHR system and are not appropriate for other conditions, treatments, therapeutic areas, or for other EHR systems. The process outlined in this document is variable, and not all steps will apply to every health system. Steps that are not part of a standard process should be adapted accordingly. Users should contact their system administrators or appropriate service providers for questions or clarifications. The health system is responsible for selecting message content and use of patient resources, such as copay savings cards, according to their communication protocols.

Utilizing EHR Prescribing Workflow Capabilities

Facilitate Prescribing of Mounjaro® (tirzepatide)

Saving as a "Favorite" in Oracle Health

New prescriptions for Mounjaro may require additional information that is not currently included in the EHR prescribing workflow.

- The prescribing details, including patient directions for taking the medication, or patient sig, for Mounjaro may include different options from other commonly prescribed type 2 diabetes medications
- Saving Mounjaro 2.5 mg/0.5 mL dose as a "Favorite" medication on the preference list helps ensure all prescribing details and patient instructions are accurate

Support Patient Journey by Prompting Follow-Ups

Message Center Messages

A message may be preconfigured to automatically trigger when a new prescription for Mounjaro is signed. These messages can be sent to the healthcare provider's (HCP's) inbox or care team's inbox.

The Message Center functions similarly to an email message inbox and messages may:

- Remind HCPs to follow health system protocols for patient outreach when a new Rx is ordered
- Schedule delivery for prompt patient follow-up regarding use of the Mounjaro pen at 1 week post-prescription
- Recommend specific actions, such as providing a new prescription for the 5 mg/0.5 mL dose after 4 weeks on the 2.5 mg/0.5 mL dose

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Contraindications

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Utilizing EHR Prescribing Workflow Capabilities (cont.)

Increase Awareness of the Mounjaro® (tirzepatide) Savings Card

Health systems can update their EHR to integrate savings card information with HCP notifications when the prescription is signed. Patient-facing messages regarding the savings card can be added to patient instructions in the Visit Summary.

HCP-facing messages:

- Adding Special Instructions to the Medication Order to confirm the patient's diagnosis of type 2 diabetes and confirm the patient is eligible for the savings card. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions.
- Creating Discern Alerts to notify HCPs that patients may be eligible for the Mounjaro Savings Card. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions.

Patient-facing messages:

- Adding a hyperlink to the Mounjaro Savings Card enrollment site within patient instructions in the Visit Summary using Auto Text. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions.

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Risk of Thyroid C-cell Tumors

Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or Mounjaro. Observe patients for signs and symptoms, including persistent or severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.

Oracle Health Instructions

How to Save Mounjaro® (tirzepatide) as a "Favorite" in Oracle Health

Frequently written prescriptions can be saved as a **"Favorite"** in the Oracle Health system.

"Favorites" can be saved in the HCP's individual "Favorites" List or shared with all prescribers in the practice or health system.

Benefits of saving a medication as a "Favorite" include:

- Saving time when prescribing
- Ensuring accuracy and consistency



Individual Prescriber

Individual "Favorites" appear on the HCP's "Favorites" List.

Individual "Favorites" are typically managed by individual prescribers.




Practice or Facility

Shared "Favorites" appear on the Facility List.

Shared Facility Lists are typically managed by the information technology (IT) staff.

Steps to Save Mounjaro as a "Favorite"

1. Search for Mounjaro in the **Search** field under the **Medication List** tab.
2. Select Mounjaro 2.5 mg/0.5 mL pen in the display on the **Details** tab.



An illustrative example of Medication List Search

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.

Oracle Health Instructions (cont.)

How to Save Mounjaro® (tirzepatide) as a "Favorite" in Oracle Health (cont.)

Steps to Save Mounjaro as a "Favorite" (cont.)

- On the **Details** tab, enter or confirm the **Dose, Route, Frequency, Duration, and Instructions**.
- Click the **Sign** button to save.

Details for **MOUNJARO**

Details | Order Comments | Diagnosis

Dose	*Route	*Frequency	Duration	Dispense	*Refill
2.5 mg/0.5 mL	SC SOAJ	Weekly	4 weeks	0	0

Instructions: Inject 2.5 mg once weekly for 4 weeks

Print DEA Number?: Yes No

Samples:

eRx Notes to Pharmacy:

DAW: Yes No

Type of Therapy: Acute Maintenance

Sample Expiration Date:

0 Missing Required Details | Dx Table | Orders for Cosignature | Sign

An illustrative example of the Prescription Details screen

- From the **Medications List**, right-click on the order to be designated as a Favorite.
- From the context menu, select **Add To Favorites**.

Orders | Medication List

Search: MOUNJARO | Advanced Options | Type: Outpatient

Folder:

Orders for Signature

Order Name	Details
START EMR Organization FIN:	
Medications	
MOUNJARO 2.5 mg/0.5 mL SC SOAJ	

Remove
Ordering Physician...
Add/Modify Compliance
Reference Information...
Add To Favorites...

Example of the prescription context menu screen

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported in patients treated with Mounjaro. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.

Oracle Health Instructions (cont.)

Creating a Message Within Message Center

The Message Center allows health systems to create a preconfigured message that silently and automatically triggers when a new prescription for Mounjaro® (tirzepatide) is signed. The message can be sent to the prescriber's inbox, or to the care team's group inbox, similar to an email message. These messages may include reminders for HCPs to follow health system protocols for patient outreach when a new Rx is ordered. Message Center messages can also recommend a specific action, such as an HCP signing off on a new prescription for Mounjaro when the patient is scheduled to transition to a different dose.

A multistep process is necessary to set up Oracle Health to automatically generate messages, as follows:

1. Create a Cerner Command Language (CCL) script that identifies new prescriptions for Mounjaro 2.5 mg/0.5 mL.
2. Create a Discern Rule that is fed from the CCL script.
3. Set the CCL on OPS (operations) in Olympus to run at a scheduled time.

Create a CCL Script

The CCL Script creates a data feed to the Discern Rule, which creates messages. CCL Scripts are typically set up by the health system's IT support services. When making an IT request, include the following requirements:

- Identify patients with new orders for Mounjaro 2.5 mg/0.5 mL.
- Use this group of patients as a data feed to Discern.

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Acute Kidney Injury Due to Volume Depletion

There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Mounjaro. The majority of reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Mounjaro that could lead to volume depletion, especially during dosage initiation and escalation of Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.**



Oracle Health Instructions (cont.)

Note: The following CCL Code will identify new orders for Mounjaro 2.5 mg/0.5 mL. CCL code can be copied and pasted into DiscernVisualDeveloper and compiled for local system use.

```
drop program rx_tirzepatide_reminder go
create program rx_tirzepatide_reminder

declare tirzepatidecd = f8 with constant (var_get_
code_by("DISPLAY", 200, "tirzepatide"))
declare orderedcd = f8 with constant (var_get_code_
by("DISPLAY", 6004, "Ordered"))

%i cclsource:eks_rprq3091001.inc

record REQUEST (
  1 expert_trigger = vc
  1 qual [*]
  2 person_id = f8
  2 sex_cd = f8
  2 birth_dt_tm = dq8
  2 encntr_id = f8
  2 accession_id = f8
  2 order_id = f8
  2 data [ * ]
  3 vc_var = vc
  3 double_var = f8
  3 long_var = i4
  3 short_var = i2
)

select into "NL:"
from
orders o
where
o.catalog_cd in (tirzepatidecd

and o.current_start_dt_tm between
cnvtdatetime(cnvlookbehind("49, D"), 0000) and
cnvtdatetime(cnvlookbehind("42, D"), 2359)
and o.order_status_cd in (orderedcd)
and o.orig_ord_as_flag = 1 ;prescriptions only

head report
cnt = 0
EKSOPSRequest -> expert_trigger = "rx_tirzepatide_
reminder"
detail
cnt = cnt + 1
if(mod(cnt, 100) = 1)
stat = alterlist(EKSOPSRequest->qual,cnt + 99)
endif
EKSOPSRequest->qual[cnt].person_id = o.person_id
EKSOPSRequest -> qual[cnt].order_id = o.order_id
EKSOPSRequest -> qual[cnt].encntr_id = o.encntr_id

foot report
stat = alterlist(EKSOPSRequest->qual,cnt)
with nocounter

%i cclsource:eks_run3091001.inc

set dparam = 0
call srvRequest(dparam)
call echorecord(EKSOPSRequest)
end
go
```

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Severe Gastrointestinal Adverse Reactions

Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe. In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving Mounjaro (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. Mounjaro is not recommended in patients with severe gastroparesis.

Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Mounjaro has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.

Oracle Health Instructions (cont.)

Create a Discern Rule

Open **DiscernDev** and click **New** to create a new Discern rule.

Maintenance Tab

On the **Maintenance** tab, complete the fields as appropriate:

- **Title:**
 - Name the **Discern Rule**; for example, Mounjaro Reminder.
- **Duration:**
 - Both dates default to the current date.
 - Change the **To:** field to a date in the future.
- Update other fields per the health system's guidelines.

Knowledge Tab

On the **Knowledge** tab, add information in each section as appropriate:

- **EVOKE Section.**
 - In **Evoke On** section, click **Select Evoke Event**.
 - Choose the **EXPERT_EVENT** template.
 - In the Evoke templates, search for and select **EKS_EXPERT_EVENT**.
- **TRIGGER_E** template.
 - Click **TRIGGER**.
 - Double-click **Double click in lower box**.
 - Double-click on the **phrase that displays** in the lower box to highlight the phrase.
 - Input the name of the **CCL** that you created in the previous step; for example, **rx_mounjaro_reminder**.
 - Click **Finish** to complete the Evoke template.

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Acute Gallbladder Disease

In placebo-controlled clinical trials in adults, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.

Pulmonary Aspiration During General Anesthesia or Deep Sedation

Mounjaro delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Mounjaro.


Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.

Oracle Health Instructions (cont.)

Knowledge Tab (cont.)

- **LOGIC Section.**
 - Click in the white space under the heading.
- **Logic Section.**
 - Select the **EKS_LOGIC_TRUE** template.
- **ACTION Section.**
 - Click on the white space under **Action Section**.
 - Double-click or drag the **EKS_INBOX_A** template into the Action section.
 - Search for and select appropriate **MSG_TYPE**; for example, Phone Message.
 - Link to Rule **L1**.
 - Enter **RECIPIENT**; for example, Nurse Pool.
 - Enter **SUBJECT**; for example, New Prescription Follow-up.
 - Enter **MSG**; for example, "Patient @PATIENT:1 has received a new Rx. Please follow Pt outreach protocol for follow-up."
 - **MSG_PRIORITY**: You can choose the appropriate priority.
 - MESSAGE 1: "This patient has received a new Rx. Please follow Pt outreach protocol for follow-up."
 - MESSAGE 2: "This patient has completed 4 weeks of treatment. Please follow-up with new Rx for Mounjaro."
 - Frequency: Always Automatically.

Note: Each organization will vary on which pool will receive the messages for patient outreach and the protocol for patient outreach workflow and timing. It will be up to the individual organizations how to implement timing and pools, as well as developing any associated protocol and content of messages.



An illustrative example of Action Section set up for New Prescription follow-up

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Adverse Reactions in Adults

The most common adverse reactions reported in $\geq 5\%$ of Mounjaro-treated patients in placebo-controlled trials were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Oracle Health Instructions (cont.)

Maintenance Tab

- Open the **Maintenance** tab again.
- Click **Save** to save the Discern Rule.

Implement the Discern Rule

To implement the Discern Rule after it has been saved, the following servers must be cycled:

- Server 55: CPM Process.
- Server 150: Discern Expert Server (EKS_ASYNCH_01).
- Server 151: Discern Expert Server (EKS_ASYNCH_02).
- Server 152: Discern Expert Server (EKS_ASYNCH_03).
- Server 175: Discern Expert Server (CPM.EKS).
- Server 176: Discern Event Server.

Automate the Discern Rule

To enable the Discern Rule to fire automatically, the CCL can be added to operations in Olympus. Olympus is typically set up by the health system's IT support services. When making an IT request, include the following requirement:

- Desired frequency to automatically fire the **rx_mounjaro_reminder** rule; for example, weekly.

The screenshot shows a message interface with the following elements:

- Message Header:** "Messages" and "General Messages" tabs. Action buttons: Reply, Reply All, Forward, Delete, Print, Previous, Next.
- Patient Information:**
 - Smith, Jane** (Age: 48 years, Gender: Female, EMR: FN#)
 - DOB: 1/1/1977
- Message Content:**
 - From:** [Redacted]
 - Sent:** 01/23/2025 1:23:46 PM CST
 - Subject:** New Prescription Follow-up
 - To:** [Redacted]
 - Caller:** [Redacted]
 - Action:** [Redacted]
 - Due:** [Redacted]
 - Provider:** [Redacted]
 - Document:** General Message
- Message Body:**
 - From:** [Redacted]
 - To:** [Redacted]
 - Sent:** 01/23/2025 1:23:46 PM CST
 - Subject:** New Prescription Follow-up
 - Caller Name:** [Redacted]
 - Text:** This patient has received a new Rx. Please follow Pt outreach protocol for follow-up
- Response Buttons:** Save, Save Addendum, Reject All, Accept All, Accept All and Next.

An illustrative example of a Message Center Message

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Drug Interactions

When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia. Mounjaro delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.**

Oracle Health Instructions (cont.)

Provider Reminders (Special Instructions, Discern Alert)

Adding Special Instructions to the Order Entry Screen

When an HCP searches for and selects a medication, specific Special Instructions can be displayed to remind the HCP of important considerations, such as the need to confirm the patient's diagnosis of type 2 diabetes and check eligibility for the savings card. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions.

Special Instructions are typically set up by the health system's IT support services. When making an IT request to add Special Instructions for Mounjaro® (tirzepatide), include the following information:

1. In the **Special Instructions** section, provide specific text to display; for example, use *"Confirm patient has a type 2 diabetes diagnosis and instruct patient to visit the Mounjaro website to verify eligibility for the savings card. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions."*

Details for **MOUNJARO 2.5 mg/0.5 mL** Send to: Select Routing

*Dose	*Route	*Frequency	Duration	*Dispense	*Refill
2.5 mg/0.5 mL	Subcutaneous	<input type="checkbox"/> Weekly	28 days	2 mL	0

Special Instructions: **1** Confirm patient has a type 2 diabetes diagnosis and instruct patient to visit the Mounjaro website to verify eligibility for the savings card. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions.

Type of Therapy: Acute Maintenance

DAW: Yes No

Samples: [Dropdown]

Comment Text 1: [Text Field]

Earliest Fill Date: **/**/****

Max Daily Dose: [Text Field]

PRN: [Dropdown]

Requested Refill Date: **/**/****

*Start Date/Time: 08/28/2025 1248

Stop Date/Time: **/**/****

Select Prescriber Address: [Text Field]

Print DEA Number: Yes No

Drug Form: [Dropdown]

Note to Pharmacy: [Text Field]

Max Daily Dose Unit: [Dropdown]

An illustrative example of including Special Instructions for Mounjaro

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Pregnancy

Limited data on Mounjaro use in pregnant women are available to inform on drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide. Use only if potential benefit justifies the potential risk to the fetus.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.

Oracle Health Instructions (cont.)

Provider Reminders (Special Instructions, Discern Alert) (cont.)

Creating a Discern Alert

A Discern Alert can be created to display when Mounjaro 2.5 mg/0.5 mL is ordered. The information displayed can remind the prescriber that the patient may be eligible for the Mounjaro Savings Card, but that patient attestation is required. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions.

Requesting a Discern Alert From the EHR Support Team

Health systems generally have a defined process for submitting a request. The process typically includes the submission of specific information. Providing key information for Discern Alerts requests will facilitate the setup, which is often managed by the IT team.

Key information includes:

Evoke: Defines the EHR actions which initiate the criteria filtering based on the designated logic

- For example, opening a chart, closing a chart, or placing an order.

Logic: Used to specify the criteria by which an action is triggered

- For example, adult patients 18 years or older, with a diagnosis for type 2 diabetes.

Action: Specify what should display to the end users, what options should be included, and appropriate actions for each option

- For example, a message such as "A savings card for Mounjaro is available for eligible, commercially insured patients. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions. Patient attestation is required."

Note: *When data in the patient chart meet the Discern Alert criteria, the Discern Alert automatically displays to the user.*

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Lactation

In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose. There are no available data on the effects of tirzepatide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mounjaro and any potential adverse effects on the breastfed infant from Mounjaro or from the underlying maternal condition.

Females of Reproductive Potential

Advise females using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Oracle Health Instructions (cont.)

Provider Reminders (Special Instructions, Discern Alert) (cont.)

Steps for Creating a Discern Alert

Open DiscernDev, which will open the rules application. When in the application, click the **New** button and start a brand-new rule.

1. A new rule window will open on the Maintenance tab. Fill in the fields as follows:
 - **Title:** Enter a title for your rule as per your facility's standards.
 - **Duration:** Change the To date to a date far in the future, such as 10/01/2099.
 - **Validation:** While building the rule, leave Validation as Testing. But once the rule is completed, you can change this to Production.
 - **File Name:** This field will not be fillable until you save the rule the first time. This field should be all one word, with underlines instead of spaces.
 - **Authors, Institution,** and all other fields should be set up per your facility's standards.
2. Once the **Maintenance** tab is filled out, click over to the **Knowledge** tab to begin building your rule.
3. For the **Evoke Section:**
 - Click on the **Select Evoke Event** and choose **SIGNORDER**.
 - From the list of Evoke templates on the left mid-page, choose the template **EKS_ORDER_E** to make it **Evoke 1 (E1)**.
 - For **ORD_METHOD**, click and choose **that was ordered as**.
 - For **OPT_ORDERS**, choose **Pharmacy** from the **CATALOG_TYPE** options, and then choose **M** from the list to get to the list of M synonyms.
 - Choose all appropriate **Mounjaro** synonyms that you would like to include in the rule.

The Evoke section is complete and should look like this:

An illustrative example of Evoke criteria entry

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Pediatric Use

Adverse reactions reported in pediatric patients 10 years of age and older treated with Mounjaro were similar to those reported in adults with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. The safety and effectiveness of Mounjaro have not been established and use is not recommended in patients less than 10 years of age.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.**

Oracle Health Instructions (cont.)

Provider Reminders (Special Instructions, Discern Alert) (cont.)

Steps for Creating a Discern Alert (cont.)

4. Next, click in the **Logic** section to present the Logic templates.
 - From the Logic templates, select **EKS_LOGIC_TRUE** and make it **Logic 1 (L1)**. No further configuration for this template is needed.
 - From the Logic templates, select **EKS_ORDER_INCOMING_L** and make it **Logic 2 (L2)**.
 - Set **ORD_METHOD** to **that was ordered as**.
 - Set **OPT_ORDERS** to the same Mounjaro synonyms that you did in Evoke 1 by choosing **Pharmacy** from the **CATALOG_TYPE**, then choose **M** from the list of available synonyms, and then finally select the Mounjaro synonyms.
 - From the Logic templates, select **EKS_ORDER_INC_ADDL_DETAIL_L**.
 - Set **ORD_DETAIL** first to **Order Entry Field** and then from the list of order entry fields, choose the field **Number of Refills**.
 - Set **QUALIFIER** to **Is defined (exists)**.
 - Set **L?** by clicking it, then selecting **Logic 2 (L2)** from the list. This will set the template to be linked to any orders in **Logic 2 (L2)**.

SELECT IMPORTANT SAFETY INFORMATION

WARNING: RISK OF THYROID C-CELL TUMORS

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Oracle Health Instructions (cont.)

Provider Reminders (Special Instructions, Discern Alert) (cont.)

Steps for Creating a Discern Alert (cont.)

The Logic section is complete and should look like this:

Logic Section

IF

L1 EKS_LOGIC_TRUE ✓
LOGIC is true

AND

L2 EKS_ORDER_INCOMING_L ✓
the triggering request contains an order [that was ordered as*](#) [Mounjaro 2.5 mg/0.5 mL subcutaneous...](#) whose ordering physician [OPT_QUALIFIER](#) in [OPT_ORDERDOC](#) and [FUTURE USE FUTURE USE OPTLIST](#)

AND

L3 EKS_ORDER_INC_ADDL_DETAIL_L ✓
the order detail [Number of Refills*](#) [is defined \(exists\)*](#) [LIST1](#) and [OPT_LIST2](#) for orders in [L2](#)

An illustrative example of Logic criteria entry

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Contraindications

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.




Oracle Health Instructions (cont.)

Provider Reminders (Special Instructions, Discern Alert) (cont.)

Steps for Creating a Discern Alert (cont.)

- Next, click the **Action** section to present the Action templates.
 - From the Action templates, select **EKS_ALERT_FLEX_A** and move it into **Action 1 (A1)**.
 - For **OPT_TITLE**, input the title for your Discern Rule. For example, we have used Mounjaro Savings Card.
 - For **TXT**, input something that explains what the end user needs to know for your rule. In our example, we have used the following text: *"A savings card for Mounjaro is available for eligible, commercially insured patients. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions. Patient attestation is required."*
 - For **OPT_URL_BUTTON_NAME**, input the name of the button to display. For example, we have called it Savings Card.
 - For **OPT_URL_ADDRESS**, input the URL to lead the end user to the information on the internet.

The Action section is complete and should look like this:



An illustrative example of Savings Card Action criteria entry

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Risk of Thyroid C-cell Tumors

Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Oracle Health Instructions (cont.)

Provider Reminders (Special Instructions, Discern Alert) (cont.)

Steps for Creating a Discern Alert (cont.)

6. Now, with all fields filled out, click the **Save** button and give your rule the name that you wish to compile the rule as, according to your site's standards. And finally, back on the **Maintenance** tab, change the **Validation** field from **TESTING** to **PRODUCTION**.

Note: With the rule built, you will first need to cycle the following servers:


- Server 55 – CPM Process.

Note: This rule has to be cycled just once per rule after the rule has been saved. Once the rule has been saved and Server 55 cycled, you won't have to cycle this server again for this rule.

- Server 175 – Discern Expert Server (CPM.EKS) NOTE: Any changes to the rule, you will need to cycle this server once again.
- Server 176 – Discern Event Server.

Note: Any changes to the rule, you will need to cycle this server once again.

Now when a prescription for Mounjaro is written, the following alert will pop up for the provider:



An illustrative example of Mounjaro Savings Card Alert

7. When the **Savings Card** button is clicked, it will open the default web browser for the provider's computer and the Mounjaro Savings Card website.

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or Mounjaro. Observe patients for signs and symptoms, including persistent or severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.

Please see additional Important Safety Information on the following pages and accompanying **Full Prescribing Information**, including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and **Medication Guide**. Please see **Instructions for Use** included with the pen.



Oracle Health Instructions (cont.)

Patient Instructions

Using Auto Text to Add Mounjaro® (tirzepatide) Savings Card Hyperlink to the Visit Summary

Providing eligible and commercially insured patients with access to a savings card may support starting and staying on therapy. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions. This section provides information about using Auto Text to include a link to the Mounjaro Savings Card enrollment site in the patient instructions section within a Visit Summary.

The health system may choose to develop and deploy Auto Text phrases centrally or have clinical staff set them up; if the latter, IT department support is typically not required.

Note: *Although this resource contains a suggested Auto Text title and text for illustration and convenience, the health system should independently evaluate and determine (i) which information is appropriate for capturing within the Auto Text phrase and (ii) the titles and text for any Auto Text. Health systems should not inappropriately standardize or automate processes that require patient-by-patient consideration or judgment and should appropriately train personnel on the use and limitations of Auto Text phrases before deploying them.*

Steps to Create an Auto Text

1. From within the **Patient Instructions** section of a visit note, type the desired text or phrase; for example, "You may be eligible for a savings card for your Mounjaro prescription. **Governmental beneficiaries excluded, terms and conditions apply.** You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions. Visit [Savings & Resources | Mounjaro® \(tirzepatide\)](#) to check eligibility and present the card to your pharmacist when you pick up your prescription. For additional support materials to your mobile device, text MJ to 85099."

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.




Oracle Health Instructions (cont.)

Patient Instructions (cont.)


Steps to Create an Auto Text (cont.)

2. Highlight the text to be included in the Auto Text.
3. Right-click, then select **Save As Auto Text**.



An illustrative example of the context menu for creating Auto Text

4. In the **Manage Auto Text** window, enter the name for the Auto Text; for example, use Mounjaro Savings Card.
Note: Auto Text abbreviations cannot contain spaces or underscores.
5. Add text to be included in the **Visit Summary** in the **Details** box. Select **Save** to use for the selected patient and also to save for future use.



An illustrative example of Manage Auto Text

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported in patients treated with Mounjaro. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.

Oracle Health Instructions (cont.)

Patient Instructions (cont.)

Steps to Create an Auto Text (cont.)

- When the Auto Text is saved in the **Visit Summary**, the information associated with the Auto Text is included in the Visit Summary in the Educational Materials section.

VISIT SUMMARY	
John Smith MRN: 304444	
Instructions	
from Jones, Pat, MD	
Labs ordered today	
Basic metabolic panel Complete as directed	
Lipid panel Complete as directed	
What's next	
You currently have no upcoming appointments scheduled.	
Your Medications	
⚠ Always use your most recent med list	
MOUNJARO 2.5 mg/0.5 mL	
My Summary	
You saw Jones, Pat MD on Wednesday, January 20th 2025. The following issue was addressed. Routine medical exam.	
Vital Signs:	
Height: 5'9"	BP: 110/80
Weight: 150 lb	Pulse: 80
Body Mass Index: 27	Temp: 98 F
Educational Materials	
You may be eligible for a savings card for your Mounjaro prescription. Governmental beneficiaries excluded, terms and conditions apply. You can go to www.mounjaro.lilly.com/savings-resources to see the full Terms and Conditions. Visit Savings & Resources Mounjaro® (tirzepatide) to check eligibility and present the card to your pharmacist when you pick up your prescription. For additional support materials to your mobile device, text MJ to 85099.	

An illustrative example of a Visit Summary report with a hyperlink to the Mounjaro Savings Card website and enrollment form.

SELECT IMPORTANT SAFETY INFORMATION (CONT.)

Acute Kidney Injury Due to Volume Depletion

There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Mounjaro. The majority of reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Mounjaro that could lead to volume depletion, especially during dosage initiation and escalation of Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Disclaimers

- The Customer (e.g., the physician, medical group, integrated delivery network [IDN]) shall be solely responsible for the implementation, testing, and monitoring of the instructions to ensure proper orientation in each Customer's EHR system.
- Capabilities, functionality, and set-up (customization) for each individual EHR system may vary. Lilly shall not be responsible for revising the implementation instructions it provides to any customer in the event that the Customer modifies or changes its software, or the configuration of its EHR system, after the implementation instructions have been initially provided by Lilly.
- While Lilly tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems, and Lilly shall have no liability thereto.
- While EHRs may assist providers in identifying appropriate patients for consideration of assessment, treatment, and referral, the decision and action should ultimately be decided by a provider in consultation with the patient after a review of the patient's records to determine eligibility. Lilly shall have no liability related to a provider's decision and action (or inaction) regarding any patient identified using this resource.
- The instructions have not been designed to and are not tools and/or solutions for meeting Meaningful Use, Advancing Care Information, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)/Merit-based Incentive Payment System (MIPS) Quality Measures, and/or any other quality/accreditation requirement.
- All products are trademarks of their respective holders. All rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Lilly and/or its affiliates.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Important Safety Information for Mounjaro® (tirzepatide)

WARNING: RISK OF THYROID C-CELL TUMORS

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.

Contraindications

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Mounjaro.

Risk of Thyroid C-cell Tumors

Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or Mounjaro. Observe patients for signs and symptoms, including persistent or severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.

Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Important Safety Information for Mounjaro® (tirzepatide) (cont.)

Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported in patients treated with Mounjaro. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.

Acute Kidney Injury Due to Volume Depletion

There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Mounjaro. The majority of reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Mounjaro that could lead to volume depletion, especially during dosage initiation and escalation of Mounjaro.

Severe Gastrointestinal Adverse Reactions

Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe. In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving Mounjaro (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. Mounjaro is not recommended in patients with severe gastroparesis.

Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Mounjaro has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.

Acute Gallbladder Disease

In placebo-controlled clinical trials in adults, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.

Pulmonary Aspiration During General Anesthesia or Deep Sedation

Mounjaro delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Mounjaro.

Adverse Reactions in Adults

The most common adverse reactions reported in ≥5% of Mounjaro-treated patients in placebo-controlled trials were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.

Please see additional Important Safety Information on the following page and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#) included with the pen.



Important Safety Information for Mounjaro® (tirzepatide) (cont.)

Drug Interactions

When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia. Mounjaro delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.

Pregnancy

Limited data on Mounjaro use in pregnant women are available to inform on drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide. Use only if potential benefit justifies the potential risk to the fetus.

Lactation

In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose. There are no available data on the effects of tirzepatide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mounjaro and any potential adverse effects on the breastfed infant from Mounjaro or from the underlying maternal condition.

Females of Reproductive Potential

Advise females using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

Pediatric Use

Adverse reactions reported in pediatric patients 10 years of age and older treated with Mounjaro were similar to those reported in adults with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. The safety and effectiveness of Mounjaro have not been established and use is not recommended in patients less than 10 years of age.

Dosage Forms and Strengths: Mounjaro is available as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL subcutaneous injection in a prefilled single-dose pen.


Please click to access [Prescribing Information](#), including **Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#)**.

Please see [Instructions for Use](#) included with the pen.

TR HCP ISI 19DEC2025

Mounjaro® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Oracle Health is a trademark of Oracle.

CMAT-10151 02/2026 ©Lilly USA, LLC 2026. All rights reserved.


mounjaro®
(tirzepatide) injection 0.5 mL
2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg


A MEDICINE COMPANY

